Carcinogen testing spin-out raises £1.4M

Funding round completed

Gentronix Ltd, of Manchester, UK, raised £1.4 million in a funding round led by NVM Private Equity Ltd, which invested £1 million in the deal.

The company has developed a process that enables the pharmaceutical industry to test compounds for potential carcinogenicity in the early stages of research, saving investment in drugs that ultimately fail in toxicity testing further down the drug development pathway

Gentronix was founded in 1999, as a spin-out from the University of Manchester with backing from the Manchester Technology Fund and YFM Private Equity Limited.

The company currently offers two screening kits and boasts Johnson & Johnson and GlaxoSmithKline as customers

Gentronix continues to work closely with university, and NVM’s investment was coupled with further funding from Manchester Technology Fund and YFM, along with some private investors.